Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of ZOSTAVAX in adults ≥60 years
2007-000343-10Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoster vaccine, live in herpes zoster (HZ), sponsored by Merck & Co. Primary endpoint: Serious clinical adverse experiences within 42 days. Started Sep 2007; status: completed.
02
Drugs
zoster vaccine, live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2007-000343-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000343-10.